Regeneron Pharma (REGN) PT Lowered to $785 at Cantor Fitzgerald on Disappointing Trial Results
Tweet Send to a Friend
(Updated - May 18, 2026 10:27 AM EDT)
Cantor Fitzgerald analyst Carter Gould lowered the price target on Regeneron ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Cantor Fitzgerald analyst Carter Gould lowered the price target on Regeneron ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
